tradingkey.logo
tradingkey.logo
Buscar

ENDRA Life Sciences Inc

NDRA
Añadir a la lista de seguimiento
5.330USD
+0.330+6.60%
Cierre 06/30, 16:00ETCotizaciones retrasadas 15 min
11.35MCap. mercado
PérdidaP/E TTM

Más Datos de ENDRA Life Sciences Inc Compañía

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

Información de ENDRA Life Sciences Inc

Símbolo de cotizaciónNDRA
Nombre de la empresaENDRA Life Sciences Inc
Fecha de salida a bolsaJun 28, 2017
Director ejecutivoTokman (Alexander Y)
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección3600 Green Ct Ste 350
CiudadANN ARBOR
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal48105
Teléfono17343350468
Sitio Webhttps://www.endrainc.com/
Símbolo de cotizaciónNDRA
Fecha de salida a bolsaJun 28, 2017
Director ejecutivoTokman (Alexander Y)

Ejecutivos de ENDRA Life Sciences Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de ENDRA Life Sciences Inc?

Los cinco principales accionistas de ENDRA Life Sciences Inc son: Mr. Anthony DiGiandomenico

¿Cuántas instituciones poseen acciones de ENDRA Life Sciences Inc (NDRA)?

A fecha de 2026Q1, 30 instituciones poseen acciones de ENDRA Life Sciences Inc, con un valor de mercado combinado de aproximadamente 218.33K, lo que representa el 17.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 137855.00.